If we were to ask the same question in cancer treatment today we would be met with an equally resounding “yes”: while for most cancers it is possible to achieve an initial, possibly significant, burden reduction, many patients recur with drug-resistant disease, or even progress while still under treatment.
← all excerpts
Spatial structure impacts adaptive therapy by shaping intra-tumoral competition.
1
—
—